Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus LOESTRIN 21 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 21 1 5 30 versus LOESTRIN 21 1 20.
LOESTRIN 21 1.5/30 vs LOESTRIN 21 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-labeled indication)
Prevention of pregnancyOral contraceptive therapy
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
None Documented
None Documented
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Norethindrone: 8-11 hours (terminal half-life; steady-state achieved after 5-10 days); Ethinyl estradiol: 13-27 hours (terminal half-life; significant interindividual variability due to enterohepatic recirculation).
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation and conjugation; norethindrone undergoes reduction, sulfate conjugation, and CYP3A4 metabolism.
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone is metabolized by CYP3A4 and reduction, conjugation (sulfation and glucuronidation).
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Renal: ~50% (as metabolites, primarily glucuronide conjugates of norethindrone and ethinyl estradiol); Fecal: ~35% (via bile); Urinary recovery of unchanged drug is minimal (<1%).
Ethinyl estradiol: ~97-98% (albumin); Norethindrone: ~80-90% (SHBG & albumin).
Norethindrone: ~61% bound to albumin and SHBG; Ethinyl estradiol: ~97-98% bound to albumin (not to SHBG).
Ethinyl estradiol: ~1.2-1.8 L/kg; Norethindrone: ~3.4 L/kg. Suggests extensive tissue distribution.
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 2-4 L/kg (indicating extensive tissue distribution and high lipophilicity).
Oral: Ethinyl estradiol ~38-48%, Norethindrone ~64-71% due to first-pass metabolism.
Oral: Norethindrone ~64% (due to first-pass metabolism); Ethinyl estradiol ~45% (range 30-60%, with significant first-pass conjugation to sulfate and glucuronide).
No dosage adjustment required for mild-to-moderate renal impairment. Not recommended in patients with severe renal impairment or end-stage renal disease due to limited data.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
Contraindicated in patients with acute or chronic hepatic disease, including Child-Pugh class A, B, or C. Do not use.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; consider alternative contraception.
Safety and efficacy have not been established in postmenarchal adolescents. Use same dosing as adults after menarche if deemed appropriate by clinician; weight-based dosing not applicable.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, 7 days off).
Not indicated for postmenopausal women. No specific geriatric dosing; avoid use in this population.
Not indicated for postmenopausal women. No specific geriatric dosing studies; use lowest effective dose if considered, but generally avoid due to increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use; risk increases with age and number of cigarettes smoked; women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use COCs should be strongly advised not to smoke.
["Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction)","Hypertension","Gallbladder disease","Hepatic neoplasia","Carbohydrate/lipid effects","Headache/migraine","Irregular bleeding/amenorrhea","Drug interactions (e.g., antibiotics, anticonvulsants)","Depression","Retinal thrombosis"]
["Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI)","Hepatic neoplasia risk","Ocular lesions (e.g., retinal thrombosis)","Carbohydrate metabolism alterations","Elevated blood pressure","Gallbladder disease","Depression","Interactions with enzyme-inducing drugs (e.g., rifampin, anticonvulsants)"]
["Known or suspected pregnancy","Current or past thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected carcinoma of the breast or endometrium","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known hypersensitivity to any component","Cigarette smoking in women over age 35"]
["Known or suspected pregnancy","Current or past history of thromboembolic disorders or cerebrovascular disease","Significant liver disease or liver tumors (benign or malignant)","Known or suspected estrogen-dependent neoplasia (e.g., breast cancer)","Undiagnosed abnormal uterine bleeding","Hypersensitivity to any component","Headache with focal neurological symptoms (e.g., migraine with aura) in women >35 years","Cigarette smoking in women >35 years"]
Data Pending Review
Data Pending Review
No specific food restrictions. Grapefruit may increase estrogen levels; monitor for side effects. Avoid St. John's Wort as it reduces contraceptive efficacy.
No specific food restrictions. Grapefruit juice may increase estrogen levels; consider avoiding large amounts. Alcohol is not contraindicated but may affect liver metabolism. Consult with your healthcare provider.
No increased risk of birth defects based on epidemiological studies; postmarketing reports of congenital anomalies (limb defects, cardiovascular malformations) are rare and lack consistent association. Hormonal effects may cause fetal harm if used inadvertently during pregnancy; pregnancy should be excluded before initiation. Discontinue if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy. Use during first trimester associated with cardiovascular defects, limb reduction defects, and neural tube defects. Exposure in second and third trimester increases risk of fetal feminization in male fetuses, vaginal adenosis and cervical cancer in female fetuses. No known risk in third trimester for congenital anomalies.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk (M/P ratio not established). May reduce milk production and quality, especially with higher doses. Use is generally not recommended during breastfeeding unless benefit outweighs risk.
Excreted in breast milk. Estrogen and progestin may reduce milk production and quality. M/P ratio not established. Use during breastfeeding not recommended. Alternative contraception advised until weaning.
Contraindicated in pregnancy. No dose adjustment recommended as drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not applicable due to contraindication.
Contraindicated in pregnancy. No dose adjustments applicable; discontinue immediately if pregnancy occurs.
Category C
Category C
Start on first day of menses or first Sunday after onset. Use backup contraception for 7 days if starting after day 5. Monitor for thromboembolic events, especially in smokers over 35. May cause breakthrough bleeding; counsel that this usually resolves after 3 cycles. Consider drug interactions with rifampin, some anticonvulsants, and St. John's Wort.
Loestrin 21 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. It is a low-dose monophasic oral contraceptive. For missed pills, follow standard CDC guidelines: if one pill is missed, take it as soon as remembered; if two or more are missed, consider backup contraception. The 21-day regimen has a 7-day pill-free interval. Patients with breakthrough bleeding should be counseled that this is common in the first few cycles. Use with caution in patients with a history of hypertension, migraine with aura, or thromboembolic disorders.
Take one tablet daily at the same time for 21 days, then none for 7 days.Use backup contraception (e.g., condoms) if you miss a pill or start late.Common side effects include nausea, breast tenderness, and spotting.Seek medical attention for leg pain/swelling, chest pain, or sudden severe headache.Do not smoke while taking this medication due to increased risk of blood clots.
Take one pill daily at the same time for 21 days, then none for 7 days.If you miss a pill, take it as soon as you remember. If you miss two or more, use backup contraception (e.g., condoms) for 7 days.Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.This medication does not protect against sexually transmitted infections (STIs).Do not smoke while taking this medication, especially if over age 35, as it increases risk of serious cardiovascular events.Seek medical attention if you experience severe abdominal pain, chest pain, headache, eye problems, or leg pain/swelling.